A detailed history of Hsbc Holdings PLC transactions in Coherus Bio Sciences, Inc. stock. As of the latest transaction made, Hsbc Holdings PLC holds 101,156 shares of CHRS stock, worth $171,965. This represents 0.0% of its overall portfolio holdings.

Number of Shares
101,156
Previous 103,183 1.96%
Holding current value
$171,965
Previous $178,000 41.01%
% of portfolio
0.0%
Previous 0.0%

Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$0.99 - $1.8 $2,006 - $3,648
-2,027 Reduced 1.96%
101,156 $105,000
Q2 2024

Aug 12, 2024

BUY
$1.58 - $2.51 $15,649 - $24,861
9,905 Added 10.62%
103,183 $178,000
Q1 2024

May 15, 2024

SELL
$2.02 - $3.14 $13,303 - $20,680
-6,586 Reduced 6.59%
93,278 $222,000
Q4 2023

Feb 12, 2024

BUY
$1.59 - $3.85 $26,290 - $63,659
16,535 Added 19.84%
99,864 $332,000
Q3 2023

Nov 13, 2023

BUY
$3.74 - $5.45 $148,362 - $216,196
39,669 Added 90.86%
83,329 $311,000
Q2 2023

Aug 11, 2023

SELL
$3.79 - $8.3 $11,006 - $24,103
-2,904 Reduced 6.24%
43,660 $186,000
Q1 2023

May 15, 2023

BUY
$5.89 - $10.52 $8,652 - $15,453
1,469 Added 3.26%
46,564 $318,000
Q4 2022

Feb 14, 2023

BUY
$5.69 - $10.07 $178,318 - $315,583
31,339 Added 227.82%
45,095 $357,000
Q3 2022

Nov 14, 2022

SELL
$7.17 - $13.87 $255,266 - $493,799
-35,602 Reduced 72.13%
13,756 $137,000
Q2 2022

Aug 11, 2022

BUY
$5.86 - $13.23 $89,101 - $201,162
15,205 Added 44.52%
49,358 $363,000
Q1 2022

May 16, 2022

BUY
$10.92 - $16.41 $372,950 - $560,450
34,153 New
34,153 $449,000
Q3 2021

Nov 12, 2021

SELL
$12.68 - $17.79 $133,850 - $187,791
-10,556 Closed
0 $0
Q2 2021

Aug 13, 2021

BUY
$12.95 - $15.41 $136,700 - $162,667
10,556 New
10,556 $145,000
Q1 2021

May 14, 2021

SELL
$14.42 - $21.39 $222,731 - $330,389
-15,446 Closed
0 $0
Q4 2020

Feb 12, 2021

BUY
$16.56 - $18.94 $255,785 - $292,547
15,446 New
15,446 $268,000
Q3 2020

Nov 12, 2020

SELL
$17.41 - $19.89 $224,084 - $256,004
-12,871 Closed
0 $0
Q2 2020

Aug 14, 2020

SELL
$14.43 - $19.16 $47,416 - $62,959
-3,286 Reduced 20.34%
12,871 $230,000
Q1 2020

May 15, 2020

BUY
$11.67 - $22.53 $70,533 - $136,171
6,044 Added 59.76%
16,157 $259,000
Q4 2019

Feb 14, 2020

SELL
$16.33 - $21.37 $106,994 - $140,016
-6,552 Reduced 39.32%
10,113 $182,000
Q3 2019

Nov 14, 2019

BUY
$16.3 - $23.37 $271,639 - $389,461
16,665 New
16,665 $338,000

Others Institutions Holding CHRS

About Coherus BioSciences, Inc.


  • Ticker CHRS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,724,600
  • Market Cap $132M
  • Description
  • Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...
More about CHRS
Track This Portfolio

Track Hsbc Holdings PLC Portfolio

Follow Hsbc Holdings PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hsbc Holdings PLC, based on Form 13F filings with the SEC.

News

Stay updated on Hsbc Holdings PLC with notifications on news.